I will look for those. The only study that I was able to find was a phase III with only 180 participants and no information on the outcome.
Yahoo rejects the links I post. There are numerous studies and trials from the UK and 3 are starting here in the USA now. The DEA and FDA have been roadblocks to any trials here because of the obvious reasons. It's absurd. Anyway, if you Google Sativex or Epidolex you will find your way to numerous trials completed abroad, and the 3 underway in the USA. Sativex for MS spasticity and cancer pain, and Epidolex for pediatric epilepsy. CBD is a pretty remarkable compound with many indications for intractable conditions. No side effects either.
BIIB's up to 330 today. Looks like the OP's prediction was wrong and I am going to be right.
My wife has been on Avonex since shortly after it was introduced. It seemed to help with the yearly exacerbations until last year. She had an acute episode. We stopped the inflammation ( and the episode) with high CBD (cannabidiol) cannabis. I mean it stopped dead in it's tracks. She has been using it (we live in Colorado) since and is steadily improving with no exacerbations. It is the first treatment to actually improve her condition. I know Biogen is now researching cannabinoids, but are very late to this area. CBD could very well be a long term problem for any drugs treating neurological disease. BTW, my wife has stopped using Avonex. I'm not knocking Biogen or their drugs (except the crazy price), but there does seem to be a compound that treats MS symptoms and may alter the course of the disease.
wow, if you bought this in 1998 below $4 you would have killing return now at $320 in 2014
Eloctate, Alprolux, Pleglridy. etc. BIIB has had multiple FDA filings over the past 12-18 months and they will become revenue streams as they roll out.
BIIB is going to hit $350 long before it hits $250. If you're shorting it you are going to lose your shorts.
I expect BIIB to correct to $250 range , expected it after earnings we never got it ...but one is coming likely this month on a market correction
Sentiment: Strong Sell
This is going to $400. You so called smart guys can sell. This is an amazing company.
Sentiment: Strong Buy